# OSR Health, Inc.: financial statements, quarterly

OSRH · OTC · CIK 1840425 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/osrh.md) · [Financials](/companies/osrh/financials.md) · [Filings](/companies/osrh/filings.md) · [Insiders](/companies/osrh/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/osrh/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | not reported | not reported | [0.9](/filings/0001213900-25-045947.md) | [0.9](/filings/0001213900-25-076461.md) | [0.8](/filings/0001213900-25-109054.md) | [0.9 d](/filings/0001213900-26-037395.md) | [0.8](/filings/0001213900-26-055492.md) | [1.1](/filings/0001213900-26-089904.md) | [0.6](/filings/0001213900-25-109054.md) | [0.4 d](/filings/0001213900-26-037395.md) | [0.5](/filings/0001213900-26-055492.md) | [0.3](/filings/0001213900-26-089904.md) |
| Cost of revenue | $m | not reported | not reported | [0.7](/filings/0001213900-25-045947.md) | [0.6](/filings/0001213900-25-076461.md) | [0.6](/filings/0001213900-25-109054.md) | [0.8 d](/filings/0001213900-26-037395.md) | [0.6](/filings/0001213900-26-055492.md) | [1.1](/filings/0001213900-26-089904.md) | [0.4](/filings/0001213900-25-109054.md) | [0.3 d](/filings/0001213900-26-037395.md) | [0.3](/filings/0001213900-26-055492.md) | [0.2](/filings/0001213900-26-089904.md) |
| Gross profit | $m | not reported | not reported | [0.2](/filings/0001213900-25-045947.md) | [0.2](/filings/0001213900-25-076461.md) | [0.2](/filings/0001213900-25-109054.md) | [0.2 d](/filings/0001213900-26-037395.md) | [0.2](/filings/0001213900-26-055492.md) | [0.0](/filings/0001213900-26-089904.md) | [0.3](/filings/0001213900-25-109054.md) | [0.1 d](/filings/0001213900-26-037395.md) | [0.2](/filings/0001213900-26-055492.md) | [0.1](/filings/0001213900-26-089904.md) |
| Research and development | $m | not reported | not reported | [0.0](/filings/0001213900-25-045947.md) | [0.0 d](/filings/0001213900-25-076461.md) | [0.1 d](/filings/0001213900-25-109054.md) | [0.0 d](/filings/0001213900-26-037395.md) | [0.1](/filings/0001213900-26-055492.md) | [0.1 d](/filings/0001213900-26-089904.md) | [(0.0) d](/filings/0001213900-25-109054.md) | [0.2 d](/filings/0001213900-26-037395.md) | [0.1](/filings/0001213900-26-055492.md) | [0.1 d](/filings/0001213900-26-089904.md) |
| Selling, general and administrative | $m | [0.4](/filings/0001193125-24-258772.md) | [0.9 d](/filings/0001193125-24-099137.md) | [3.5](/filings/0001213900-25-045947.md) | [3.4](/filings/0001213900-25-076461.md) | [3.7](/filings/0001213900-25-109054.md) | [1.8 d](/filings/0001213900-26-037395.md) | [3.1](/filings/0001213900-26-055492.md) | [5.3](/filings/0001213900-26-089904.md) | [4.1](/filings/0001213900-25-109054.md) | [6.5 d](/filings/0001213900-26-037395.md) | [3.8](/filings/0001213900-26-055492.md) | [3.1](/filings/0001213900-26-089904.md) |
| Operating income | $m | not reported | not reported | [(3.3)](/filings/0001213900-25-045947.md) | [(3.2)](/filings/0001213900-25-076461.md) | [(3.6)](/filings/0001213900-25-109054.md) | [(1.6) d](/filings/0001213900-26-037395.md) | [(2.9)](/filings/0001213900-26-055492.md) | [(5.2)](/filings/0001213900-26-089904.md) | [(3.8)](/filings/0001213900-25-109054.md) | [(6.4) d](/filings/0001213900-26-037395.md) | [(3.7)](/filings/0001213900-26-055492.md) | [(3.0)](/filings/0001213900-26-089904.md) |
| Interest expense | $m | not reported | not reported | [0.0](/filings/0001213900-25-045947.md) | [0.0](/filings/0001213900-25-076461.md) | [0.0](/filings/0001213900-25-109054.md) | [0.0 d](/filings/0001213900-26-037395.md) | [0.0](/filings/0001213900-26-055492.md) | [0.0](/filings/0001213900-26-089904.md) | [0.0](/filings/0001213900-25-109054.md) | [0.4 d](/filings/0001213900-26-037395.md) | [0.0](/filings/0001213900-26-055492.md) | [0.0](/filings/0001213900-26-089904.md) |
| Income tax | $m | [0.1](/filings/0001193125-24-258772.md) | [0.2 d](/filings/0001213900-25-034116.md) | [0.0](/filings/0001213900-25-045947.md) | [(1.0)](/filings/0001213900-25-076461.md) | [(0.1)](/filings/0001213900-25-109054.md) | [(0.5) d](/filings/0001213900-26-037395.md) | not reported | not reported | [(1.3)](/filings/0001213900-25-109054.md) | [(0.5) d](/filings/0001213900-26-037395.md) | [(0.5)](/filings/0001213900-26-055492.md) | [(0.4)](/filings/0001213900-26-089904.md) |
| Net income | $m | [0.1](/filings/0001193125-24-258772.md) | [(0.1) d](/filings/0001213900-25-034116.md) | [(0.1)](/filings/0001193125-24-258772.md) | [(0.1)](/filings/0001193125-24-258772.md) | [(0.2)](/filings/0001193125-24-258772.md) | [(2.0) d](/filings/0001213900-25-034116.md) | [(11.4)](/filings/0001213900-26-089904.md) | [(5.2)](/filings/0001213900-26-089904.md) | [(3.2)](/filings/0001213900-25-109054.md) | [(7.2) d](/filings/0001213900-26-037395.md) | [(3.5)](/filings/0001213900-26-089904.md) | [(1.0)](/filings/0001213900-26-089904.md) |
| Diluted EPS | $ per share | [0.01](/filings/0001193125-24-258772.md) | not reported | [(0.01)](/filings/0001193125-24-139407.md) | [(0.02)](/filings/0001193125-24-202828.md) | [(0.06)](/filings/0001193125-24-258772.md) | not reported | [(1.04)](/filings/0001213900-26-055492.md) | not reported | not reported | not reported | [(0.08)](/filings/0001213900-26-055492.md) | not reported |
| Basic EPS | $ per share | [0.01](/filings/0001193125-24-258772.md) | not reported | [(0.60)](/filings/0001213900-25-045947.md) | [(0.41)](/filings/0001213900-25-076461.md) | [(1.56)](/filings/0001213900-25-109054.md) | not reported | [(1.04)](/filings/0001213900-26-055492.md) | [0.02](/filings/0001213900-26-089904.md) | [(0.10)](/filings/0001213900-25-109054.md) | not reported | [(0.09)](/filings/0001213900-26-055492.md) | [(0.02)](/filings/0001213900-26-089904.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax, us-gaap:Revenues
- Cost of revenue: us-gaap:CostOfRevenue
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense, us-gaap:InterestExpenseNonoperating
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss, us-gaap:ProfitLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [0.1](/filings/0000898432-23-000769.md) | [0.0](/filings/0001213900-25-034116.md) | [0.0](/filings/0001193125-24-139407.md) | [0.1](/filings/0001193125-24-202828.md) | [0.0](/filings/0001193125-24-258772.md) | [0.3](/filings/0001213900-26-037395.md) | [1.6](/filings/0001213900-25-045947.md) | [1.6](/filings/0001213900-25-076461.md) | [2.2](/filings/0001213900-25-109054.md) | [1.7](/filings/0001213900-26-089904.md) | [1.6](/filings/0001213900-26-055492.md) | [1.5](/filings/0001213900-26-089904.md) |
| Current assets | $m | [0.1](/filings/0000898432-23-000769.md) | [0.0](/filings/0001213900-25-034116.md) | [0.1](/filings/0001193125-24-139407.md) | [0.2](/filings/0001193125-24-202828.md) | [0.0](/filings/0001193125-24-258772.md) | [2.3](/filings/0001213900-26-037395.md) | [3.5](/filings/0001213900-25-045947.md) | [2.9](/filings/0001213900-25-076461.md) | [3.2](/filings/0001213900-25-109054.md) | [2.8](/filings/0001213900-26-089904.md) | [2.9](/filings/0001213900-26-055492.md) | [2.9](/filings/0001213900-26-089904.md) |
| Total assets | $m | [72.1](/filings/0000898432-23-000769.md) | [36.6](/filings/0001213900-25-034116.md) | [37.3](/filings/0001193125-24-139407.md) | [20.6](/filings/0001193125-24-202828.md) | [20.9](/filings/0001193125-24-258772.md) | [175](/filings/0001213900-26-037395.md) | [175](/filings/0001213900-25-045947.md) | [185](/filings/0001213900-25-076461.md) | [177](/filings/0001213900-25-109054.md) | [171](/filings/0001213900-26-089904.md) | [172](/filings/0001213900-26-055492.md) | [167](/filings/0001213900-26-089904.md) |
| Current liabilities | $m | [1.1](/filings/0000898432-23-000769.md) | [2.0](/filings/0001213900-25-034116.md) | [2.7](/filings/0001193125-24-139407.md) | [3.4](/filings/0001193125-24-202828.md) | [3.9](/filings/0001193125-24-258772.md) | [3.5](/filings/0001213900-26-037395.md) | [13.9](/filings/0001213900-25-045947.md) | [15.9](/filings/0001213900-25-076461.md) | [15.0](/filings/0001213900-25-109054.md) | [17.2](/filings/0001213900-26-089904.md) | [17.9](/filings/0001213900-26-055492.md) | [15.7](/filings/0001213900-26-089904.md) |
| Total liabilities | $m | [3.2](/filings/0000898432-23-000769.md) | [4.1](/filings/0001213900-25-034116.md) | [4.8](/filings/0001193125-24-139407.md) | [5.5](/filings/0001193125-24-202828.md) | [6.0](/filings/0001193125-24-258772.md) | [32.0](/filings/0001213900-26-037395.md) | [42.3](/filings/0001213900-25-045947.md) | [46.3](/filings/0001213900-25-076461.md) | [43.1](/filings/0001213900-25-109054.md) | [44.2](/filings/0001213900-26-089904.md) | [44.8](/filings/0001213900-26-055492.md) | [41.7](/filings/0001213900-26-089904.md) |
| Long-term debt | $m | not reported | not reported | not reported | not reported | not reported | [0.5](/filings/0001213900-26-037395.md) | [0.3](/filings/0001213900-25-045947.md) | not reported | [0.0](/filings/0001213900-25-109054.md) | not reported | [0.3](/filings/0001213900-26-055492.md) | [0.3](/filings/0001213900-26-089904.md) |
| Current portion of debt | $m | [1.0](/filings/0000898432-23-000769.md) | [2.0](/filings/0001193125-24-099137.md) | [2.7](/filings/0001193125-24-139407.md) | [3.3](/filings/0001193125-24-202828.md) | [3.9](/filings/0001193125-24-258772.md) | not reported | [0.2](/filings/0001213900-25-045947.md) | [0.6](/filings/0001213900-25-076461.md) | not reported | not reported | [0.2](/filings/0001213900-26-055492.md) | [0.3](/filings/0001213900-26-089904.md) |
| Short-term borrowings | $m | not reported | not reported | not reported | not reported | not reported | [1.8](/filings/0001213900-26-037395.md) | [1.6](/filings/0001213900-25-045947.md) | [1.8](/filings/0001213900-25-076461.md) | [1.9](/filings/0001213900-25-109054.md) | [2.3](/filings/0001213900-26-089904.md) | [2.2](/filings/0001213900-26-055492.md) | [2.1](/filings/0001213900-26-089904.md) |
| Shareholders' equity | $m | [(2.5)](/filings/0001193125-24-258772.md) | [(3.9)](/filings/0001213900-25-034116.md) | [(4.3)](/filings/0001193125-24-258772.md) | [(4.9)](/filings/0001193125-24-258772.md) | [(5.8)](/filings/0001193125-24-258772.md) | [(8.3)](/filings/0001213900-25-034116.md) | [132](/filings/0001213900-26-089904.md) | [139](/filings/0001213900-26-089904.md) | [134](/filings/0001213900-25-109054.md) | [127](/filings/0001213900-26-089904.md) | [127](/filings/0001213900-26-089904.md) | [125](/filings/0001213900-26-089904.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebtNoncurrent
- Current portion of debt: us-gaap:DebtCurrent, us-gaap:LongTermDebtCurrent
- Short-term borrowings: us-gaap:ShortTermBorrowings
- Shareholders' equity: us-gaap:StockholdersEquity, us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(0.1) d](/filings/0001193125-24-258772.md) | [(0.3) d](/filings/0001213900-25-034116.md) | [(0.5)](/filings/0001213900-25-045947.md) | [(0.5) d](/filings/0001213900-25-076461.md) | [(0.7) d](/filings/0001213900-25-109054.md) | [(0.2) d](/filings/0001213900-26-037395.md) | [(0.1)](/filings/0001213900-26-055492.md) | [(0.5) d](/filings/0001213900-26-089904.md) | [(2.7) d](/filings/0001213900-25-109054.md) | [(1.1) d](/filings/0001213900-26-037395.md) | [(1.0)](/filings/0001213900-26-055492.md) | [(2.4) d](/filings/0001213900-26-089904.md) |
| Share repurchases | $m | [0.0 d](/filings/0001193125-24-258772.md) | [36.0 d](/filings/0001213900-25-034116.md) | not reported | not reported | [0.0 d](/filings/0001193125-24-258772.md) | [19.2 d](/filings/0001213900-25-034116.md) | not reported | not reported | not reported | not reported | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | period not labelled (2022-06-30) | period not labelled (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q1 FY2026 (2026-03-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [1.5](/filings/0000898432-23-000624.md) | [1.5](/filings/0000898432-23-000769.md) | [5.2](/filings/0001193125-24-139407.md) | [9.1](/filings/0001193125-24-202828.md) | [9.1](/filings/0001193125-24-258772.md) | [5.6](/filings/0001193125-24-139407.md) | [4.9](/filings/0001193125-24-202828.md) | [4.0](/filings/0001193125-24-258772.md) | [10.9](/filings/0001213900-26-055492.md) | [34.3](/filings/0001213900-26-055492.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 35,118,692 at 2026-08-10, from the cover of the [10-Q filed 2026-08-14](/filings/0001213900-26-089904.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:49 ET. No prices; not investment advice.